Patient Guide: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 35 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06073132
Status: 🟢 Enrolling Now
Condition: Generalized Epidermolysis Bullosa Simplex
Phase: PHASE2, PHASE3

Where You Can Participate

This study is available at 35 locations across the country.

Top locations include:
  • • Rancho Santa Margarita, California
  • • Stanford, California
  • • Aurora, Colorado
  • • And 32 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) - Join Clinical Trial NCTNCT06073132

How to Join This Clinical Trial - NCTNCT06073132

Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for Generalized Epidermolysis Bullosa Simplex. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Generalized Epidermolysis Bullosa Simplex. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Generalized Epidermolysis Bullosa Simplex
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2, PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06073132 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 35 locations. Find a study site near you:

Clinical Research Site

Rancho Santa Margarita, California 92688 - United States

Status: RECRUITING

Clinical Research Site

Stanford, California 94304 - United States

Status: RECRUITING

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: RECRUITING

Clinical Research Site

Miami, Florida 33146 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60611 - United States

Status: RECRUITING

Clinical Research Site

Stony Brook, New York 11790 - United States

Status: RECRUITING

Clinical Research Site

Cincinnati, Ohio 45229 - United States

Status: RECRUITING

Clinical Research Site

Charleston, South Carolina 29425 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78218 - United States

Status: RECRUITING

Clinical Research Site

Kogarah, - Australia

Status: RECRUITING

And 25 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2, PHASE3 clinical trial for Generalized Epidermolysis Bullosa Simplex:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships